|Table of Contents|

Research progress of CDK4/6 inhibitor in the treatment of non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 03
Page:
479-486
Research Field:
Publishing date:

Info

Title:
Research progress of CDK4/6 inhibitor in the treatment of non-small cell lung cancer
Author(s):
LI Wenjie1; 2; 3; JIA Yingjie1; 3; 4
1.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300000;2.Tianjin University of Traditional Chinese Medicine,Tianjin 300000;3.National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300000;4.Tianjin Institute of Traditional Chinese Medicine Cancer,Tianjin 300000
Keywords:
CDK4/6 inhibitor; non-small cell lung cancer; research progress
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2025.03.020
Abstract:
Lung cancer is currently the most prevalent and fatal type of cancer,with non-small cell lung cancer (NSCLC) accounting for 80% to 85%.Dysregulation of the cell cycle is a critical factor in the initiation and progression of malignancies,including lung cancer,with approximately 80% of human tumors exhibiting abnormalities in the cyclin D-CDK4/6-INK4-RB pathway.CDK4/6 inhibitors exert their antitumor effects by blocking the activity of CDK4/6,thereby interrupting the cell cycle of tumor cells.These agents have already been approved for clinical use in breast cancer treatment.Current research findings regarding CDK4/6 inhibitors in non-small cell lung cancer suggest that targeting the cell cycle represents a promising new therapeutic strategy.This article summarizes the mechanisms by which CDK4/6 inhibitors exert their antitumor effects,as well as some recent preclinical and clinical research outcomes,with the aim of providing new insights and strategies for future investigations targeting CDK4/6 in the treatment of non-small cell lung cancer.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2024,74(3):229-263.
［2］ PAPAVASSILIOU KA,GOGOU VA,PAPAVASSILIOU AG.Harnessing tumor mechanobiology in NSCLC treatment［J］.Arch Bronconeumol,2024,60(8):523-525.
［3］ PASSARO A,BRAHMER J,ANTONIA S,et al.Managing resistance to immune checkpoint inhibitors in lung cancer:treatment and novel strategies［J］.J Clin Oncol,2022,40(6):598-610.
［4］ MORRISON L,LOIBL S,TURNER NC.The CDK4/6 inhibitor revolution-a game-changing era for breast cancer treatment［J］.Nat Rev Clin Oncol,2024,21(2):89-105.
［5］ LYU S,YANG J,LIN J,et al.CDK4/6 inhibitors in lung cancer:current practice and future directions［J］.Eur Respir Rev,2024,33(171):230145.
［6］ O' SULLIVAN CC,CLARKE R,GOETZ MP,et al.Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive,ERBB2-negative breast cancer:a review［J］.JAMA Oncol,2023,9(9):1273-1282.
［7］ ZHANG J,XU D,ZHOU Y,et al.Mechanisms and implications of CDK4/6 inhibitors for the treatment of NSCLC［J］.Front Oncol,2021,11:676041.
［8］ ZHOU Y,TAO L,QIU J,et al.Tumor biomarkers for diagnosis,prognosis and targeted therapy［J］.Signal Transduct Target Ther,2024,9(1):132.
［9］ FASSL A,GENG Y,SICINSKI P.CDK4 and CDK6 kinases:From basic science to cancer therapy［J］.Science,2022,375(6577):eabc1495.
［10］ JIN X,DING D,YAN Y,et al.Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression［J］.Mol Cell,2019,73(1):22-35.e6.
［11］ ZHANG J,BU X,WANG H,et al.Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance［J］.Nature,2018,553(7686):91-95.
［12］ FRANCO J,BALAJI U,FREINKMAN E,et al.Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities［J］.Cell Rep,2020,32(1):107793.
［13］ CONROY LR,LORKIEWICZ P,HE L,et al.Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells［J］.Cancer Cell Int,2020,20:280.
［14］ LI P,ZHANG X,GU L,et al.P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib［J］.PLoS One,2019,14(10):e0223084.
［15］ THANGAVEL C,BOOPATHI E,LIU Y,et al.Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non-small cell lung cancer［J］.Clin Cancer Res,2018,24(6):1402-1414.
［16］ HINO H,IRIYAMA N,KOKUBA H,et al.Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes［J］.Cancer Sci,2020,111(6):2132-2145.
［17］ NAZ S,COOK JA,MITCHELL JB.Abemaciclib:A multi-functional radiation modifier［J］.Oncotarget,2019,10(12):1230-1232.
［18］ LIU D,LIU H,GAN J,et al.LY2874455 and abemaciclib reverse FGF3/4/19/CCND1 amplification mediated gefitinib resistance in NSCLC［J］.Front Pharmacol,2022,13:918317.
［19］ LIU M,LIU H,CHEN J.Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)［J］.Oncol Rep,2018,39(3):901-911.
［20］ SUN CY,TALUKDER M,CAO D,et al.Gilteritinib enhances anti-tumor efficacy of CDK4/6 inhibitor,abemaciclib in lung cancer cells［J］.Front Pharmacol,2022,13:829759.
［21］ NIE H,ZHOU X,DU S,et al.Palbociclib overcomes afatinib resistance in non-small cell lung cancer［J］.Biomed Pharmacother,2019,109:1750-1757.
［22］ QIN Q,LI X,LIANG X,et al.CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC)［J］.Thorac Cancer,2020,11(9):2389-2397.
［23］ SHI R,LI M,RAGHAVAN V,et al.Targeting the CDK4/6-Rb pathway enhances response to PI3K inhibition in PIK3CA-mutant lung squamous cell carcinoma［J］.Clin Cancer Res,2018,24(23):5990-6000.
［24］ GOPALAN PK,VILLEGAS AG,CAO C,et al.CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition［J］.Oncotarget,2018,9(100):37352-37366.
［25］ GOLDMAN JW,MAZIERES J,BARLESI F,et al.A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage Ⅳ NSCLC with KRAS mutation:JUNIPER［Z］.American Society of Clinical Oncology，2018.
［26］ WANG Y,LI X,LIU X,et al.Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer［J］.Cancer Biol Med,2019,16(1):66-83.
［27］ ROBERTS PJ,KUMARASAMY V,WITKIEWICZ AK,et al.Chemotherapy and CDK4/6 inhibitors:unexpected bedfellows［J］.Mol Cancer Ther,2020,19(8):1575-1588.
［28］ CAO J,ZHU Z,WANG H,et al.Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer［J］.Oncogene,2019,38(21):4125-4141.
［29］ KE Y,LIAO CG,ZHAO ZQ,et al.Combining a CDK4/6 inhibitor with pemetrexed inhibits cell proliferation and metastasis in human lung adenocarcinoma［J］.Front Oncol,2022,12:880153.
［30］ NAZ S,SOWERS A,CHOUDHURI R,et al.Abemaciclib,a selective CDK4/6 inhibitor,enhances the radiosensitivity of non-small cell lung cancer in vitro and in vivo［J］.Clin Cancer Res,2018,24(16):3994-4005.
［31］ FERNANDEZ-AROCA DM,ROCHE O,SABATER S,et al.P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib:Implication in cancer therapy［J］.Cancer Lett,2019,451:23-33.
［32］ ZHOU W,WANG W,LIANG Y,et al.The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer［J］.Nat Commun,2023,14(1):4212.
［33］ BAI X,GUO ZQ,ZHANG YP,et al.CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy［J］.Nat Commun,2023,14(1):1247.
［34］ ZHANG J,BU X,WANG H,et al.Author correction:Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance［J］.Nature,2019,571(7766):E10.
［35］ LAI AY,SORRENTINO JA,DRAGNEV KH,et al.CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy［J］.J Immunother Cancer,2020,8(2):e000847.
［36］ DENG J,WANG ES,JENKINS RW,et al.CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation［J］.Cancer Discov,2018,8(2):216-233.
［37］ AHN ER,MANGAT PK,GARRETT-MAYER E,et al.Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations:results from the targeted agent and profiling utilization registry study［J］.JCO Precis Oncol,2020,4:757-766.
［38］ ZHANG C,WANG H.Therapeutic utility of Lung-MAP:ushering into an era of genomic and biomarker-driven clinical trials［J］.Signal Transduct Target Ther,2021,6(1):141.
［39］ CHO BC,GOLDBERG SB,KIM DW,et al.A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer［J］.Expert Opin Investig Drugs,2022,31(7):747-757.
［40］ SANTORO A,SU WC,NAVARRO A,et al.Phase Ⅰb/Ⅱ study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer［J］.Lung Cancer,2022,166:170-177.
［41］ LI C,HART L,OWONIKOKO TK,et al.Trilaciclib dose selection:an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/Ⅱa studies in patients with extensive-stage small cell lung cancer［J］.Cancer Chemother Pharmacol,2021,87(5):689-700.
［42］ ABRAHAM I,ONYEKWERE U,DENIZ B,et al.Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy［J］.J Med Econ,2021,24(suppl_1):71-83.
［43］ DANIEL D,KUCHAVA V,BONDARENKO I,et al.Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer:A multicentre,randomised,double-blind,placebo-controlled Phase Ⅱ trial［J］.Int J Cancer,2021,148(10):2557-2570.
［44］ O' LEARY B,CUTTS RJ,HUANG X,et al.Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer［J］.J Natl Cancer Inst,2021,113(3):309-317.
［45］ XUE Y,ZHAI J.Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance［J］.Int J Clin Exp Pathol,2024,17(7):189-207.

Memo

Memo:
全国名中医传承工作室建设项目（编号：974022）；天津市研究生科研创新项目（编号：YJSKC-20232001）
Last Update: 1900-01-01